FY2025 EPS Estimates for CLDX Cut by Cantor Fitzgerald

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Research analysts at Cantor Fitzgerald dropped their FY2025 EPS estimates for Celldex Therapeutics in a research report issued on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceutical company will post earnings per share of ($3.67) for the year, down from their prior forecast of ($3.61). Cantor Fitzgerald currently has a "Overweight" rating and a $67.00 target price on the stock. The consensus estimate for Celldex Therapeutics' current full-year earnings is ($2.48) per share.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.02. The business had revenue of $1.18 million during the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%.

A number of other equities analysts have also recently commented on the company. HC Wainwright reissued a "buy" rating and set a $80.00 price target on shares of Celldex Therapeutics in a report on Friday, February 28th. The Goldman Sachs Group reduced their price objective on Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. Finally, UBS Group started coverage on Celldex Therapeutics in a report on Thursday, February 13th. They issued a "buy" rating and a $44.00 target price for the company. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $55.38.

Remove Ads

Celldex Therapeutics Price Performance

NASDAQ:CLDX traded down $1.11 during trading hours on Thursday, reaching $19.56. 743,762 shares of the company were exchanged, compared to its average volume of 896,742. The company has a market capitalization of $1.30 billion, a P/E ratio of -7.61 and a beta of 1.76. Celldex Therapeutics has a 1-year low of $18.61 and a 1-year high of $48.37. The business has a 50 day moving average of $23.38 and a 200 day moving average of $28.39.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. KBC Group NV raised its stake in Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 495 shares during the period. Invesco Ltd. lifted its position in shares of Celldex Therapeutics by 2.1% during the fourth quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company's stock worth $1,064,000 after purchasing an additional 871 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in Celldex Therapeutics by 215.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 878 shares in the last quarter. Swiss National Bank raised its position in Celldex Therapeutics by 1.2% during the 4th quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company's stock valued at $2,964,000 after purchasing an additional 1,400 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky lifted its stake in Celldex Therapeutics by 5.1% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 42,628 shares of the biopharmaceutical company's stock worth $1,449,000 after acquiring an additional 2,070 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.